OTCMKTS:OXBDF - Oxford BioMedica Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $10.80 0.00 (0.00 %) (As of 08/17/2018 04:00 PM ET)Previous Close$10.80Today's Range$10.80 - $10.8052-Week Range$4.50 - $22.50Volume5 shsAverage Volume500 shsMarket Capitalization$738.53 millionP/E RatioN/ADividend YieldN/ABeta0.98 Company ProfileAnalyst RatingsChartHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company operates through Partnering and R&D segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company's products under development include OXB-102 that has completed Phase I/II trial for the treatment of Parkinson's disease; OXB-202, which is in a Phase I/IIa trial preparation for the prevention of corneal graft rejection; OXB-301, a cancer vaccine which is in a Phase I/II trial; and OXB-302, which is based on an autologous T-cell that is engineered using a lentiviral vector to express a chimeric antigen receptor targeting multiple cancers, as well as OXB-201 that is in Phase I/II trial for the treatment of ?wet' age-related macular degeneration and diabetic retinopathy. It is also developing SAR 422459 that is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869, a gene-based therapy that is in Phase I/II trial for the treatment of Usher syndrome 1B. The company has partnerships with Sanofi, GlaxoSmithKline, Novartis, Green Cross LabCell, and Immune Design Corp. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom. Receive OXBDF News and Ratings via Email Sign-up to receive the latest news and ratings for OXBDF and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Private households Sub-IndustryN/A SectorMedical SymbolOTCMKTS:OXBDF CUSIPN/A Webwww.oxfordbiomedica.co.uk Phone44-18-6578-3000 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$37.67 million Price / Sales18.83 Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding Shares65,680,000Market Cap$738.53 million Oxford BioMedica (OTCMKTS:OXBDF) Frequently Asked Questions What is Oxford BioMedica's stock symbol? Oxford BioMedica trades on the OTCMKTS under the ticker symbol "OXBDF." What is the consensus analysts' recommendation for Oxford BioMedica? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford BioMedica in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oxford BioMedica. Who are some of Oxford BioMedica's key competitors? Some companies that are related to Oxford BioMedica include Sophos Group (SPHHF), WILLIAM HILL PL/ADR (WIMHY), SALZGITTER AG/ADR (SZGPY), PETROFAC Ltd/ADR (POFCY), Loomis (LOIMF), Udg Healthcare (UDHCF), BRITVIC PLC/S (BTVCY), NIHON KOHDEN Co/ADR (NHNKY), Aurora Cannabis (ACBFF), Mail Ru Group (MLRYY), OUTOKUMPU OYJ/ADR (OUTKY), Grafton Group (GROUF), BR Malls Participacoes (BRMSY), Schaeffler (SCFLF) and INDRA SISTEMAS/ADR (ISMAY). Who are Oxford BioMedica's key executives? Oxford BioMedica's management team includes the folowing people: Mr. John Dawson, CEO & Exec. Director (Age 58)Mr. Peter Nolan, Chief Bus. Officer & Exec. Director (Age 65)Mr. Timothy William Watts, Exec. Officer (Age 60)Mr. Stuart Paynter, CFO & DirectorDr. James Miskin Ph.D., Chief Technology Officer Has Oxford BioMedica been receiving favorable news coverage? News headlines about OXBDF stock have trended somewhat positive on Saturday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Oxford BioMedica earned a news and rumor sentiment score of 0.10 on Accern's scale. They also assigned news coverage about the company an impact score of 46.46 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Oxford BioMedica. How do I buy shares of Oxford BioMedica? Shares of OXBDF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Oxford BioMedica's stock price today? One share of OXBDF stock can currently be purchased for approximately $10.80. How big of a company is Oxford BioMedica? Oxford BioMedica has a market capitalization of $738.53 million and generates $37.67 million in revenue each year. How can I contact Oxford BioMedica? Oxford BioMedica's mailing address is Windrush Court Transport Way, Oxford X0, OX4 6LT. The company can be reached via phone at 44-18-6578-3000. MarketBeat Community Rating for Oxford BioMedica (OTCMKTS OXBDF)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 45 (Vote Outperform)Underperform Votes: 44 (Vote Underperform)Total Votes: 89MarketBeat's community ratings are surveys of what our community members think about Oxford BioMedica and other stocks. Vote "Outperform" if you believe OXBDF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OXBDF will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/18/2018 by MarketBeat.com StaffFeatured Article: How are Outstanding Shares Different from Authorized Shares?